NRIX
Nurix Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -1.4% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | +2 | 57.55M | $1.40B | +9 | −7 |
| Q1 2026 | 81 | +9 | 58.06M | $899.96M | +14 | −5 |
| Q4 2025 | 72 | -4 | 55.79M | $1.06B | n/a | −4 |
| Q3 2025 | 18 | +1 | 36.35M | $335.90M | +1 | n/a |
| Q2 2025 | 14 | -2 | 38.82M | $442.11M | n/a | −2 |
| Q1 2025 | 13 | 0 | 15.31M | $181.88M | +1 | −1 |
| Q4 2024 | 13 | -1 | 15.53M | $292.61M | +1 | −2 |
| Q3 2024 | 13 | -1 | 13.04M | $292.98M | +1 | −2 |
| Q2 2024 | 14 | n/a | 12.64M | $263.85M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.19M | -11.1% | $37.88M | 0.0% | ▼ Trim | 4 | SEC ↗ ×7 |
| 2 | T. Rowe Price ✦ | 2.91M | -3.1% | $34.61M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 2.86M | +2.1% | $33.99M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.72M | +8.8% | $20.49M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | ARK Investment Management ✦ | 1.59M | +4.0% | $18.90M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 1.32M | +54.7% | $15.65M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 874.40K | +106.2% | $10.39M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 257.52K | +90.6% | $3.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | PRIMECAP Management ✦ | 232.00K | 0.0% | $2.76M | 0.0% | Held | 4 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 218.45K | -75.0% | $2.60M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 59.92K | -46.9% | $711,885 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 59.50K | New | $706,860 | 0.0% | New | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 11.67K | -83.5% | $138,615 | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $706,860 | 0.0% |
Exited
| Norges Bank | $6.01M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 194 holders, 116.98M shares, $1.75B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.45K sh · $36,300
Director · 22.58K sh · $528,528
Officer · 1.45K sh · $36,982
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology